Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Kymera Therapeutics, Inc. announced the pricing of its public offering of $250.8 million, consisting of 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants for ...

Kymera will lead all research activities for the CDK2 program, while Foster City, Calif., biopharmaceutical company Gilead will have global rights to develop, manufacture and commercialize all ...

Kymera Therapeutics Announces Pricing of $250 Million Public Offering Provided by GlobeNewswire Jun 27, 2025, 3:56:15 AM. WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Kymera Therapeutics Info Justine Koenigsberg Vice President, Investor Relations [email protected] [email protected] 857-285-5300 ...